An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer

Anthony Fields, M. S. Berger, Charles Henderson et al.|Journal of Clinical Oncology|2005

Cited by 48